Year Founded
2008
Ownership
Public
Employees
~500
Therapeutic Areas
HematologyOncology
Stage
Commercial
Modalities
Small molecule

Karyopharm Therapeutics General Information

Lead product XPOVIO (selinexor) approved and commercialized for multiple myeloma and DLBCL. Pipeline includes programs in endometrial cancer and myelofibrosis.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Newton, Massachusetts
United States

Drug Pipeline

selinexor
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Karyopharm Therapeutics's pipeline data

Book a demo

Key Partnerships

Foundation Medicine, Menarini, Antengene, Neopharm, FORUS

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Karyopharm Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Karyopharm Therapeutics's complete valuation and funding history, request access »

Karyopharm Therapeutics Licensing Deals

AssetLicenseeDateTherapeutic Area
selinexorMenariniDec 1, 2021Oncology
selinexorAntengeneMay 1, 2020Oncology
eltanexorAntengeneMay 1, 2020Oncology
KPT-9274AntengeneMay 1, 2020Oncology
selinexorMenariniDec 1, 2021
selinexorHealthcare Royalty PartnersSep 1, 2019
selinexorAntengeneN/A
selinexorHealthcare Royalty PartnersSep 14, 2019
selinexorHealthcare RoyaltyMay 1, 2024Oncology
Healthcare Royalty PartnersSep 14, 2019
selinexorHealthcare Royalty PartnersSep 14, 2019
selinexorHealthcare Royalty ManagementMay 8, 2024Oncology
selinexorHealthcare RoyaltyMay 8, 2024Oncology
selinexorMenariniN/AOncology
selinexorHealthcare Royalty Partners IVSep 1, 2019
selinexorMenariniN/A
selinexorAntengeneN/AOncology
You're viewing 2 of 17 licensing deals. Get the full list »